Medtronic announced it has received CE Mark for its Micra AV2 and Micra VR2, the next generation of its miniature, leadless pacemakers. Micra AV2 and Micra VR2, the world’s smallest pacemakers, provide longer battery life and easier programming than prior Micra pacemakers, while still delivering the many benefits of leadless pacing such as reduced complications compared to traditional pacemakers. This CE Mark milestone follows FDA approval for the Micra AV2 and VR2 devices in 2023.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MDT:
- Farapulse approval coming sooner than expected for Boston Scientific, says BTIG
- NeuroPace ‘primed for continued outperformance’ in 2024, says Lake Street
- Medtronic price target raised to $87 from $84 at Truist
- Medtronic recalls StealthStation S8 application version 2.0, 2.0.1 due to glitch
- Medtronic management to meet with BTIG